Lack of reduction in body fat after treatment with insulin-like growth factor-I in two children with growth hormone gene deletions

Journal of Endocrinological Investigation

Volumn 23, Issue 4, 2000, Pages 258-262

  Arnhold, Ivo J P ^a   Oliveira, S B ^a   Osorio, M G F ^a   Carrilho, A J F ^a   Nicolau, W ^a   Bianco, A C ^a   Mendonca, B B ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Body composition; Body fat; GH deficiency; GH gene deletions; IGF I treatment

Indexed keywords

GROWTH HORMONE; RECOMBINANT SOMATOMEDIN C;

ARTICLE; BODY COMPOSITION; BODY FAT; BONE DENSITY; BONE MINERALIZATION; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; FEMALE; GENE DELETION; GROWTH HORMONE DEFICIENCY; GROWTH RATE; HORMONAL THERAPY; HUMAN; LEAN BODY WEIGHT; MALE;

EID: 0034019788     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03343719     Document Type: Article

References (19)

1. Richelsen B. Action of growth hormone in adipose tissue. Horm. Res. 1997, 48 (Suppl. 5): 105-110.
2. Rosen T., Bengtsson B.A. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990, 336: 285-288.
3. Boot A.M., Engels M.A.M.J., Boerma GJ.M., Krenning E.P., de Muinck Keizer-Schrama S.M.P.F. Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency. J. Clin. Endocrinol. Metab. 1997, 82: 2423-2428.
4. Degerblad M., Elgingy N., Hall K., Sjöberg H.E., Thoren M. Potent effect of recombinant human growth hormone on bone mineral density and body composition in adults with panhypopituitarism. Acta Endocr. (Copenh) 1992, 126: 387-393.
5. Laron Z., Klinger B. Body fat in Laron syndrome patients: effect of insulin-like growth factor I treatment. Horm. Res. 1993, 40: 16-22.
6. Guevara-Aguirre J., Rosenbloom A.L., Vasconez O., Martinez V., Gargosky S.E., Allen L., Rosenfeld R.G. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: Comparison of two dosage levels and to GH-treated GH deficiency. J. Clin. Endocrinol. Metab. 1997, 82: 629-633.
7. Underwood L.E., Backeljauw P., Duncan V., GHIS Collaborative Group. Effects of insulin-like growth factor I treatment on statural growth, body com position and phenotype of children with growth hormone insensitivity syndrome. Acta Paediatr. Scand. 1999, Suppl. 428: 182-184.
8. Kamijo T., Phillips J.A. III Detection of molecular heterogeneity in GH-1 gene deletions by analysis of polymerase chain reaction amplification products. J. Clin. Endocrinol. Metab. 1992, 74: 786-789.
9. Arnhold I.J.P., Oliveira S.B., Osorio M.G.F., Mendonca B.B. Insulin-like growth factor-I treatment in two children with growth hormone gene deletions. J. Pediatr. Endocrinol. Metab. 1999, 12: 499-506.
10. Boot A.M., Bouquet J., de Ridder M.A.J., Krenning E.P., de Muinck Keizer-Schrama S.M.P.F. Determinants of body composition measured by dual-energy X-ray absorptiometry in Dutch children and adolescents. Am. J. Clin. Nutr. 1997, 66: 232-238.
11. Carrilho A.J.F., Medina W.L., Nakandakare E.R., Quintão E.C.R. Plasma cholesteryl ester transfer protein is lowered by treatment of hypercholesterolemia with cholestyramine. Clin. Pharmacol. Ther. 1997, 62: 82-88.
12. Osorio M.G.F., Bianco A.C., Estefan V., Segura T.C., Arnhold I.J.P., Nicolau W., Mendonca B.B. Body composition and bone mass of children with hypopituitarism following six months of human growth hormone therapy. Arq. Bras. Endocrinol. Metabol. 1998, 42: 357-362.
13. Ranke M.B., Savage M.O., Chatelain P.G., Preece M.A., Rosenfeld R.G., Blum M.F., Wilton P. Insulin-like growth factor I improves height in growth hormone insensitivity: Two years results. Horm. Res. 1995, 44: 253-264.
14. Backeljauw P.F., Underwood L.E., GHIS Collaborative Group. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome - A clinical research center study. J. Clin. Endocrinol. Metab. 1996, 81: 3312-3317.
15. Klinger B., Laron Z. Three year treatment of children with Laron syndrome. J. Pediatr. Endocrinol. Metab. 1995, 8: 149-158.
16. Woods K.A., Camacho-Hübner C., Savage M.O., Clark A.J.L. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. New Engl. J. Med. 1996, 335: 1363-1367.
17. Heinrichs C., Vis H.L., Bergmann P., Wilton P., Bourguignon J.P. Effects of 17 months treatment using recombinant insulin-like growth factor-I in two children with growth hormone insensitivity (Laron) syndrome. Clin. Endocrinol. 1993, 38: 647-651.
18. Rudling M., Olivecrona H., Eggertsen G., Angelin B. Regulation of rat hepatic low density lipoprotein receptors - in vivo stimulation by growth hormone is not mediated by insulin-like growth factor I. J. Clin. Invest. 1996, 97: 292-299.
19. Rudling M., Norstedt G., Olivecrona H., Reihnér E., Gustafsson J.-A., Angelin B. Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc. Natl. Acad. Sci. USA. 1992, 89: 6983-6987.